NAD+ Therapy Shows Measurable Epigenetic Age Reversal in New Clinical Trial
A 12-week randomised controlled trial finds IV NAD+ supplementation reduces biological age markers by an average of 2.4 years, with sustained effects at 6-month follow-up. Longevity clinics offering NAD+ protocols are already citing the data.
The case for NAD+ as a core longevity intervention just got significantly stronger. A new randomised controlled trial published in Nature Aging followed 186 adults aged 45–72 over 12 weeks of intravenous NAD+ supplementation, measuring biological age via the GrimAge epigenetic clock before and after intervention.
The results: participants receiving the full-dose IV protocol showed an average biological age reduction of 2.4 years, compared to 0.3 years in the oral supplement group and no significant change in placebo. At 6-month follow-up, the IV group retained roughly 60% of the improvement.
What this means for longevity clinics
NAD+ IV therapy is already offered at most comprehensive longevity programs — Progevita, SHA Wellness, Next Health, and others. What changes is the evidence base. Until now, much of the clinical rationale rested on preclinical data and mechanistic plausibility. This trial provides the kind of controlled evidence that both clinicians and patients increasingly demand.
For clinics, this creates a clear narrative advantage: NAD+ is no longer just a biohacking trend. It’s a measurable intervention with documented epigenetic outcomes.
Protocol details
The trial used a 500mg IV infusion twice weekly for 12 weeks — a protocol broadly consistent with what most premium longevity clinics currently offer. Researchers noted that the oral supplement group, despite high compliance, showed minimal epigenetic benefit, reinforcing the view that bioavailability via IV is critical for this application.
Side effects were mild: transient flushing and nausea during infusion in 18% of participants, resolving without intervention. No serious adverse events were recorded.
Open questions
The study doesn’t answer how long effects persist beyond 6 months, what the optimal maintenance frequency is, or how NAD+ stacks with other interventions (hyperbaric oxygen, peptide therapy, or stem cells) in a combined protocol. These are the questions the next wave of trials — several already underway — will need to address.
For now, the data supports what many longevity practitioners have observed clinically: NAD+ works, IV delivery matters, and the effects are real enough to measure.